Periodic Reporting for period 1 - EndPD (ENDPD- SLOWING DOWN PARKINSON’S DISEASE PATHOLOGICAL PROGRESSION.)
Reporting period: 2023-07-01 to 2024-06-30
Parkinson's Disease (PD) currently lacks effective treatments to slow its progression, causing significant health and financial challenges for patients and their families. Fastprinciple’s therapeutic solution for Parkinson's Disease (PD) aims to slow disease progression. By slowing down the progression of PD, Fastprinciple’s solution promises significant benefits for patients and their caregivers, enhancing quality of life and reducing economic burdens. The company also plans to apply this approach to other neurological disorders, expanding its impact and commercial opportunities. Fastprinciple is dedicated to advancing this innovative treatment and collaborating with key partners to bring it to market successfully.
Economically, the solution could yield a benefit of $75,891 per patient, disrupting the PD treatment market and enhancing the EU’s economic competitiveness, especially with an estimated 17 million PD patients by 2040. Environmentally, Fastprinciple is committed to ensure sustainable. Job creation our the project future plans includes hiring additional R&D staff and other key personnel. Aligning with UN Sustainable Development Goals, the solution aims to ensure healthy lives (Goal 3), support economic growth and employment (Goal 8), and foster innovation (Goal 9) by developing new molecules for other neurological disorders.
The current grant, aimed to support Fastprinciple extending its patent protection to several countriesand to developed an exploitation plan through discussions with key players in the pharmaceutical industry, investors, and advisors. These discussions, facilitated by direct contacts and participation in international conferences, were vital for refining Fastprinciple’s R&D strategy, aligning financial requirements, adjusting business plans, and identifying potential investors and customers. This collaborative approach aims to support the next stages of Fastprinciple’s pipeline and business development, moving towards clinical trials and financial sustainability.
Economically, the solution could yield a benefit of $75,891 per patient, disrupting the PD treatment market and enhancing the EU’s economic competitiveness, especially with an estimated 17 million PD patients by 2040. Environmentally, Fastprinciple is committed to ensure sustainable. Job creation our the project future plans includes hiring additional R&D staff and other key personnel. Aligning with UN Sustainable Development Goals, the solution aims to ensure healthy lives (Goal 3), support economic growth and employment (Goal 8), and foster innovation (Goal 9) by developing new molecules for other neurological disorders.
The current grant, aimed to support Fastprinciple extending its patent protection to several countriesand to developed an exploitation plan through discussions with key players in the pharmaceutical industry, investors, and advisors. These discussions, facilitated by direct contacts and participation in international conferences, were vital for refining Fastprinciple’s R&D strategy, aligning financial requirements, adjusting business plans, and identifying potential investors and customers. This collaborative approach aims to support the next stages of Fastprinciple’s pipeline and business development, moving towards clinical trials and financial sustainability.
We have expanded and monitored the geographical reach of our patent (PCT: WO2023/144742A1).
We have developed an exploitation plan which includes an investigator brochure template with guidelines, an asset valuation and an updated business plan, and a table of conferences and communication activities. To accelerate our project, we attended several scientific and business conferences, submitted different grant application and have attracted two crucial Key Opinion Leaders (KoLs) to our team.
We have developed an exploitation plan which includes an investigator brochure template with guidelines, an asset valuation and an updated business plan, and a table of conferences and communication activities. To accelerate our project, we attended several scientific and business conferences, submitted different grant application and have attracted two crucial Key Opinion Leaders (KoLs) to our team.
There are no scientific results or outputs for the proposed project to be disseminated. Nevertheless, we are currently using the conclusion on the identified need, both R&D and financial needs for grants submissions, pitch presentations to pharma’s and investors, to increase our chances of gathering financial support. We also are incorporating the acquired knowledge in the preparation of grant.
As for the dissemination, the acquired knowledge has been exploited to sensitize the government players and the general public on the demands of this type of business project and on the need of both involvements to accelerate it.
The success of the present project depends on gathering the right financial support to fulfill the remaining steps of its pipeline development.
With the project we were able to prepare a strong exploitation plan for our project.
As for the dissemination, the acquired knowledge has been exploited to sensitize the government players and the general public on the demands of this type of business project and on the need of both involvements to accelerate it.
The success of the present project depends on gathering the right financial support to fulfill the remaining steps of its pipeline development.
With the project we were able to prepare a strong exploitation plan for our project.